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ABSTRACT 
Back ground 
Breast cancer is associated with up regulation, down regulation of normal 
antigens or abnormal antigens. These antigens are very useful candidates as 
targets for the different breast cancer therapies and for vaccination trials. 
Objectives 
This study was done to characterize abnormal antigens, extract one of them 
and to produce monoclonal antibodies against the extracted antigen. 
Methods 
          One hundred and twenty Sudanese female patients were included in this 
study after informed consent. The mean age was 47.2 years (16-80). Two 
tissue samples were obtained from each patient and they were confirmed as 
normal and cancerous breast tissues microscopically. 2D PAGE was used to 
analyze the protein content of samples. LC/MS and nr.fasta database search 
were used for separation and identification of the abnormal proteins. 
Results 
          Three different patterns of 2D PAGE results were obtained, the first 
pattern involved detection of four abnormal proteins in 26.7% of the patient 
cancerous tissues while they were undetected in the normal tissues of the same 
patients. In the second 2D PAGE result pattern the cancerous and the normal 
tissues of 67.5% patients were identical and they did not contain the four 
abnormal proteins while the third 2D PAGE pattern involved the presence of 
two abnormal antigens (from the four) in the cancerous tissues of 5.8% of the 
patients and they were absent from the normal tissues of the same patients. 
The four abnormal proteins were identified as, human Thioredoxin (D60n 
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mutant), X-ray crystal structure of human galectin-1, retrocopy of 
tropomyosin 3(rcTPM3) and beta-tropomyosin (isoform 2). The primary and 
the secondary structures were obtained from the SWISSPROT and the PDB 
databases. Beta-tropomyosin spot was extracted and used as antigen for 
monoclonal antibody production. Monoclonal antibody against beta-
tropomyosin with a concentration of 0.35mg/ml and a G11 anti beta-
tropomyosin  hybridoma cell line were produced. The monoclonal antibody 
was with single band and approximately 30 KDa  molecular weight. However, 
some tests were done to determine the specificity of the produced monoclonal 
antibody.   
Conclusions 
          In conclusion, breast cancer tissues are associated with abnormal 
antigens, but with low incidence rate; this strongly favors the individualization 
of breast cancer diagnosis and treatment. 
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 اﻟﺨﻼﺻﺔ
 اﻟﻤﻘﺪﻣﺔ
هﺬﻩ . ن اﻟﺜﺪى ﺑﺎزدﻳﺎد او ﻧﻘﺼﺎن ﺑﻌﺾ اﻟﺒﺮوﺗﻴﻨﺎت اﻟﻄﺒﻴﻌﻴﺔ او وﺟﻮد ﺑﺮوﺗﻴﻨﺎت ﻣﺤﻮرةﻳﺘﻤﻴﺰ ﺳﺮﻃﺎ
اﻟﺒﺮوﺗﻴﻨﺎت اﻟﻤﺤﻮرة ﻳﻤﻜﻦ اﺳﺘﺨﺪاﻣﻬﺎ آﻤﺴﺘﻘﺒﻼت ﻟﻼﻧﻮاع اﻟﻤﺨﺘﻠﻔﺔ ﻻدوﻳﺔ ﺳﺮﻃﺎن اﻟﺜﺪى آﻤﺎ اﻧﻬﺎ ﻳﻤﻜﻦ 
  .ان ﺗﺴﺘﺨﺪم ﻻﻧﺘﺎج ﻣﺼﻞ ﻟﺴﺮﻃﺎن اﻟﺜﺪى
 اﻻهﺪاف
رة ﻓﻰ اﻧﺴﺠﺔ ﺛﺪى ﺳﺮﻃﺎﻧﻴﺔ و ﻣﻌﺮﻓﺔ ﺗﺮآﻴﺒﻬﺎ اﺟﺮﻳﺖ هﺬﻩ اﻟﺪراﺳﺔ ﻟﻐﺮض اآﺘﺸﺎف ﺑﺮوﺗﻴﻨﺎت ﻣﺤﻮ
  .    واﺳﺘﺨﻼص اﺣﺪ هﺬﻩ اﻟﺒﺮوﺗﻴﻨﺎت واﻧﺘﺎج اﺟﺴﺎم ﻣﻀﺎدة ﺿﺪ اﺣﺪ هﻀﻪ اﻟﺒﺮوﺗﻴﻨﺎت اﻟﻤﺤﻮرة
  اﻟﺒﺤﺚﻃﺮق 
( 08-61)  ﺳﻨﺔ 2.74آﺎن ﻣﺘﻮﺳﻂ اﻟﻌﻤﺮ . ﺷﻤﻠﺖ هﺬﻩ اﻟﺪراﺳﻪ ﻣﺎﺋﻪ و ﻋﺸﺮون ﻣﺮﻳﻀﺔ ﺑﺴﺮﻃﺎن اﻟﺜﺪى. 
ﺴﻴﺞ اﻟﺴﺮﻃﺎﻧﻰ واﺧﺮى ﻣﻦ اﻟﺴﻠﻴﻢ وﻗﺪ اآﺪت هﺬﻩ اﻻﻧﺴﺠﺔ ﻋﻴﻨﺔ ﻣﻦ اﻟﻨ، أﺧﺬت ﻋﻴﻨﺘﺎن ﻣﻦ آﻞ ﻣﺮﻳﻀﻪ. 
ﺣﻠﻠﺖ اﻟﻌﻴﻨﺎت ﻻآﺘﺸﺎف ﻣﺤﺘﻮاهﺎ اﻟﺒﺮوﺗﻴﻨﻰ ﺑﺎﺳﺘﺨﺪام ﺗﻘﻨﻴﺔ اﻟﺮﺣﻼن . ﺑﺎﻟﺼﻔﺎت اﻟﻌﺎﻣﺔ و اﻟﻤﺠﻬﺮﻳﺔ
اﻟﻜﻬﺮﺑﺎﺋﻰ ﺛﻨﺎﺋﻴﺔ اﻻﺗﺠﺎﻩ و ﻟﻤﻌﺮﻓﺔ و اﻟﺒﺮوﺗﻴﻨﺎت اﻟﻤﺤﻮرﻩ وﺧﻮاﺻﻬﺎ اﺳﺘﺨﺪﻣﺖ ﺗﻘﻨﻴﺘﺎ اﻟﻔﺼﻞ اﻟﻠﻮﻧﻰ 
  .ﺛﻢ اﻟﺒﺤﺚ ﻓﻰ ﻣﻮﺳﻮﻋﺎت اﻟﺒﺮوﺗﻴﻨﺎت اﻟﻌﺎﻟﻤﻴﺔ، اﻟﺴﺎﺋﻠﺔ و اﻟﻤﻄﻴﺎف اﻟﻀﻮﺋﻰ
 اﻟﻨﺘﺎﺋﺞ
ﻓﻰ اﻟﻨﻮع اﻻول اﺣﺘﻮت اﻻﻧﺴﺠﺔ ، ﺣﺼﻞ ﻋﻠﻰ ﺛﻼﺛﺔ اﻧﻮاع ﻣﻦ ﻧﺘﺎﺋﺞ ﺗﻘﻨﻴﺔ اﻟﺮﺣﻼن اﻟﻜﻬﺮﺑﻰ ﺛﻨﺎﺋﻴﺔ اﻟﺘﺠﺎﻩ 
ﻓﻴﻤﺎ ﻳﺨﺺ ، % 7.62اﻟﺴﺮﻃﺎﻧﻴﺔ ﻋﻠﻰ ارﺑﻌﺔ ﺑﺮوﺗﻴﻨﺎت ﻣﺤﻮرة و آﺎﻧﺖ ﻧﺴﺒﺔ اﻟﻤﺮﺿﻰ ﻓﻰ هﺬا اﻟﻨﻮع 
ﺠﺔ اﻟﺴﺮﻃﺎﻧﻴﺔ ﻋﻠﻰ اى ﻣﻦ اﻟﺒﺮوﺗﻴﻨﺎت اﻟﻤﺤﻮرة اﻻرﺑﻌﺔ و آﺎﻧﺖ ﻧﺴﺒﺔ اﻟﻨﻮع اﻟﺜﺎﻧﻰ ﻟﻢ ﺗﺤﺘﻮى اﻻﻧﺴ
و ﻓﻰ اﻟﻨﻮع اﻟﺜﺎﻟﺚ اﺣﺘﻮت اﻻﻧﺴﺠﺔ اﻟﺴﺮﻃﺎﻧﻴﺔ ﻋﻠﻰ ﺑﺮوﺗﻴﻨﻴﻦ % 5.76اﻟﻤﺮﺿﻰ اﻟﺬﻳﻦ ﺣﻤﻠﻮا هﺬا اﻟﻨﻮع 
ﺗﻢ اﻟﻨﻌﺮف %. 8.5ﻣﻦ اﻻرﺑﻌﺔ ﺑﺮوﺗﻴﻨﺎت اﻟﻤﺤﻮرﻩ و آﺎﻧﺖ ﻧﺴﺒﺔ اﻟﻤﺮﺿﻰ اﻟﺬﻳﻦ ﻳﺘﻤﻴﺰون ﺑﻬﺬﻩ اﻟﺼﻮرﻩ 
اﻟﺘﺮآﻴﺐ ، (ن 06اﻟﺒﺮوﺗﻴﻦ اﻟﻤﺤﻮر  د) اﻟﻤﺤﻮرة اﻻرﺑﻌﺔ وهﻰ اﻟﺜﺎﻳﻮرﻳﺪوآﺴﻴﻦ اﻟﺒﺸﺮى ﻋﻠﻰ اﻟﺒﺮوﺗﻴﻨﺎت 
اﻟﻨﻮع ) و اﻟﺒﻴﺘﺎ ﺗﺮﺑﻮﻣﺎﻳﻮزﻳﻦ  3اﻟﺼﻮرﻩ اﻟﺮاﺟﻌﻪ ﻟﻠﺘﺮوﺑﻮﻣﺎﻳﻮزﻳﻦ، اﻟﺒﺸﺮى 1- اﻟﺒﻠﻮرى اﻟﺴﻴﻨﻰ ﻟﻠﻘﺎﻻآﺘﻴﻦ
ﻣﻀﺎدة اﺣﺎدﻳﺔ واﺳﺘﺨﺪم ﻓﻰ اﻧﺘﺎج اﺟﺴﺎم ( اﻟﻨﻮع اﻟﺜﺎﻧﻰ ) اﺳﺘﺨﻠﺺ ﺑﺮوﺗﻴﻦ اﻟﺒﻴﺘﺎ ﺗﺮوﺑﻮﻣﺎﻳﻮزﻳﻦ(. اﻟﺜﺎﻧﻰ 
وﺟﺪ ان اﻻﺟﺴﺎم اﻟﻤﻀﺎدة  .اﻧﺘﺠﺖ اﻻﺟﺴﺎم اﻟﻤﻀﺎدة اﺣﺎدﻳﺔ اﻟﻤﻨﺸﺄ و اﻟﺨﻼﻳﺎ اﻟﻬﺠﻴﻦ اﻟﻤﻨﺘﺠﺔ ﻟﻬﺎ. اﻟﻤﻨﺸﺄ
 
 
VIX 
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  ﻤﻠﺨﺺاﻟ
ﺧﻠﺼﺖ هﺬﻩ اﻟﺪراﺳﺔ اﻟﻰ ان وﺟﻮد ﺑﺮوﺗﻴﻨﺎت ﻣﺤﻮرة ﻓﻰ ﻋﻴﻨﺎت اﻧﺴﺠﺔ اﻟﺜﺪى اﻟﺴﺮﻃﺎﻧﻴﺔ  ﺑﻨﺴﺒﺔ ﺗﺮدد  
ﻗﻠﻴﻠﺔ ﻳﻘﻮى اﻻﺗﺠﺎﻩ ﻧﺤﻮ ﻣﻌﺎﻟﺠﺔ آﻞ ﻣﺮﻳﺾ ﺑﺴﺮﻃﺎن اﻟﺜﺪى ﻋﻠﻰ ﺣﺪة اﻋﺘﻤﺎدًا ﻋﻠﻰ ﻧﻮع اﻟﺒﺮوﺗﻴﻨﺎت 
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CHAPTER ONE 
Introduction  
Breast cancer, abnormal antigens and monoclonal antibodies 
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CHAPTER ONE  
Introduction 
1.1-Epidemiology of breast cancer: 
          Breast cancer is the most common cancer among women in Africa accounting for 
about 20% of all cancer incidences [1]. Breast cancer has the second highest associated 
mortality world wide [2]. 
          In Sudan, cancer is third killer disease after malaria and viral pneumonia [3]. An 
epidemiological study in East Africa region including Sudan discovered that, the breast 
cancer is in leading position amongst all female cancers but with a lower proportion of 
women below 30 years [4]. However the incidence and prevalence of cancer were 
determined in Sudan due to absence of cancer registry program. 
1.2 Breast cancer risk factors 
          Many cases of breast cancer occur in women with no obvious risk factors. This 
means that women need to be alert in watching for possible changes in their breasts, 
performing self examinations, and scheduling clinical breast examinations and 
mammograms. It is likely that risk factors influence the development of breast cancer. 
Some of these include:  
Age: 
          The risk of developing breast cancer increases as a woman ages, with the majority 
of breast cancer increases in women over the age 50. At the age 30, a woman's risk of 
developing breast cancer is one in 2525. By the age 50, her chances are one in 50, rising 
to one in 14 by the age 70 [5]. 
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 Race: 
          Although white women are more likely to develop breast cancer, black women are 
more likely to die from the disease. The reasons for this are unclear and probably involve 
both socioeconomic and biologic factors [6].  
A family history of breast cancer: 
          Women who have a first degree relative (mother, sister, daughter) diagnosed with 
breast cancer are at increased risk of the disease. More than one first degree relative with 
breast cancer elevates that risk [7].  
 Previous history of breast cancer: 
          Women who have had breast cancer in one breast have three to four times the risk 
of breast cancer in their opposite breast [8]. 
A genetic predisposition: 
          Mutations to the BRCA1 or BRCA2 genes are associated with increased breast 
cancer risk. Screening tests are available to test for known mutations to these genes, but 
are recommended for every one and only following appropriate genetic counseling. 
Researchers estimate that breast cancers caused by these genes make up only 2% to 3% 
of all breast cancers. 
          BRCA1 is a gene located on chromosome 17 while BRCA2 is located on 
chromosome 13. Until recently, it was not clear what the function of these genes, but a 
related protein in yeast revealed their normal role: they participate in repairing radiation 
induced breaks in the double stranded DNA. It is thought that mutations in BRCA1 or 
BRCA2 might disable this mechanism, leading to more errors in DNA replication and 
ultimately to cancerous growth [9].  
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 Estrogen exposure: 
          Estrogen is a hormone in women that controls the development of secondary sex 
characteristics (such as breast development). A woman's production of estrogen decreases 
at menopause. Doctors think that exposure to estrogen for a long time may increase 
breast cancer risk. 
• A long menstrual history: woman who began menstruating before age 12 or went 
through menopause after 55 have a higher risk of breast cancer because their 
breast cells have been exposed to estrogen for longer periods of time.  
• Late or no pregnancies: Women who have their first pregnancy after age 30 or 
who have never had a full – term pregnancy have risk of breast cancer. Pregnancy 
may protect against breast cancer because it pushes breast cells into their final 
phase of maturation.  
• Estrogen in medication: Recent use of oral contraceptives or hormone 
replacement therapy (HRT), or long term use of (HRT), may increase a woman 
risk of breast cancer [10]. 
 X- Ray and breast cancer: 
          It is clear that excessive X ray radiation increases the risk of breast cancer in 
women treated therapeutically with X-rays for acute and chronic breast conditions and in 
women with pulmonary tuberculosis whose artificial pneumothorax treatments were 
monitored by fluoroscopic chest X-ray [11]. 
A typical hyperplasia: 
          This is a condition characterized by abnormal, but not cancerous cells. A typical 
hyperplasia is a risk factor of breast cancer [12]. 
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Life style factors: 
          As other types of cancer, studies continue to show that various habits may 
contribute to the development of breast cancer. These include: 
• Obesity: According to a new study, being obese or even overweight 
increases a woman's risk of breast cancer. 
• Lack of exercise: Exercise lowers hormone levels and boosts the immune 
system; lack of exercise contribute to obesity. 
• Alcohol use: Drinking more than one alcoholic drink per day may raise the 
risk of breast cancer [10]. 
Radiation: 
          High doses of radiation may increase a woman's risk of breast cancer. An increased 
risk of breast cancer has been observed in long term survivors of atomic bombs and 
patients with lymphoma treated with radiation therapy to the chest [13].  
1.3 Diagnosis and types of breast cancer: 
          Breast cancer is diagnosed clinically and confirmed by imaging, cytology and 
histopathology [14]. 
          Bloom Richardson grading system is the most current cancer grading system used 
for breast cancer. It uses the degree of tubule formation, the mitotic index and the nuclear 
pleomorphism of tumor cells to grade the breast cancer [15]. Each of the three features is 
assigned a score ranging from 1 to 3. The scores are then added together to obtain score 
range from 3 to 9. The result of this scoring system is three grades, 3-5 grade I tumor  
and designed well-differentiated, 6-7  grade II tumor which is  moderately- differentiated  
and 8-9  grade III tumor  and this is the poorly- differentiated [15].  
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          The famous system for breast cancer staging is the TNM system [16]. This system 
uses three criteria to judge the stage of the cancer : the tumor itself (T) , the lymph nodes 
around the tumor (N) , and if the tumor has spread to the rest of the body (M). There are 
five stages from stage 0 to stage IV. The stage provides a common way of describing the 
cancer. [16] 
Stage 0 : Ductal carcinoma in situ is cancer that has not spread past the ducts or lobules 
of the breast . It is called non invasive cancer.  
Stage 1 : The tumor is small and has not spread to the lymph nodes   
(T1, N0, M0). 
Stage IIa : Any one of these conditions : 
• The tumor is less than 2cm and has spread to the axillary lymph nodes (T1, N1, 
M0). 
• The tumor is between 2 and 5 cm but has not spread to the axillary lymph nodes 
     (T2, N0, M0). 
• There is no evidence of the tumor in the breast, but there is cancer in the axillary 
lymph nodes (T0, N1, M0). 
Stage IIb: Any one of these conditions: 
• The tumor is between 2 and 5 cm and has spread to the axillary lymph nodes (T2, 
N, M0) . 
• The tumor is larger than 5cm but has not spread to the axillary lymph nodes (T3, 
N0, M0).  
Stage IIIa: Any of these conditions: 
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• The tumor is smaller than 5cm and has spread to axillary lymph nodes that are 
attached to each other or other structures  
      (T2, N2, M0). 
• The tumor is larger than 5cm and has spread to the axillary lymph nodes, which 
may or not be attached to each other or to other structures (T3, N1 or N2, M0). 
Stage IIIb: The tumor has spread to the chest wall or caused swelling or ulceration of the 
breast or is diagnosed as inflammatory breast cancer . It may or not have spread to the 
lymph nodes under the arm , but has not spread to other part of the body (T4, N0, N1, N2, 
M0). 
Stage IIIc: A tumor of any size has not spread to distant parts of the body, but has spread 
to the lymph nodes above the clavicle, or both the nodes inside the breast or under the 
arm (any T, N3, M0). 
Stage IV : The tumor can be any size and has spread to distant sites in the body , usually 
the bones , lung , liver , or brain (any T , any N , M1)[16]. 
1.4 Treatment of breast cancer 
          Even though the doctor will tailor the treatment for breast cancer to patient's 
disease and personal situation, there are some general steps in the logic of treating the 
disease. Primarily, the initial therapy for early stage disease is aimed at eliminating any 
visible tumor. Therefore doctors will recommend surgery to remove the tumor with or 
without radiation therapy. 
          The next step in the management of early disease is to reduce the risk of the disease 
recurring and to eliminate any cancer cells that may remain. If a tumor is of a certain size 
or lymph nodes are involved, the doctor may recommend additional therapy, 
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chemotherapy or hormonal therapy. If the cancer recurs, the patient may choose 
additional surgery, depending on where the cancer is found, or a variety of treatments 
designed to fight distant metastases. 
          When planning the treatment for a patient's breast cancer, the doctor will consider 
many factors, including:  
• The stage and grade of the tumor. 
• The tumor's hormone status (ER, PR). 
• The patient's age and general health. 
• The patient's menopausal status. 
• The presence of known mutations to breast cancer genes. 
• Factors that may signify aggressive tumor, such as HER-2/neu amplifications 
[17].  
 Surgery: 
         Generally, the smaller the tumor, the more surgical options the patient has. The 
general types of surgery include the following:  
• A lumpectomy remove the tumor and small disease free margin of tissue around 
the tumor. Follow up radiation therapy is given to the disease site. 
• A partial mastectomy removes the tumor, an area of normal tissue, and part of the 
lining over the chest muscle where the tumor was. This surgery is similar to a 
lumpectomy. It is also called a segmental mastectomy and requires follow up 
radiation.  
• A modified radical mastectomy removes the breast, some of the underarm lymph 
nodes, and the lining over the chest muscles. 
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          For invasive breast cancer, the combination of lumpectomy or partial mastectomy, 
underarm lymph node removal, and radiation therapy has been proven in clinical trials to 
be as effective as a modified radical mastectomy in treating small tumors. 
• A total mastectomy removes the entire breast, leaving the underarm lymph nodes 
intact. This surgery is also called simple mastectomy. 
• A radical mastectomy removes the breast, chest muscles, all lymph nodes under 
the arm, and additional fat and skin. This surgery is also called the Halsted radical 
mastectomy, named after the physician who devised it. It used to be the standard 
surgical treatment for breast cancer, but it is an uncommon procedure today. 
          Women are encouraged to talk with their doctors about which surgical procedure  
is right for them. More aggressive surgery is not always better and may result in 
additional complications.   
          Women who undergo a total mastectomy may wish to consider breast 
reconstruction, which is surgery to rebuild the breast. Reconstruction may be done with 
tissue from another part of the body, or with synthetic implants. The woman may choose 
to have this done at the time of mastectomy, or at some point in the future. 
          Because both lumpectomies and partial mastectomies leave a good portion of the 
breast intact, it is important that the surgeon make sure that none of the cancer has spread. 
Therefore, the surgeon, also has to evaluate the lymph nodes under the arm to make sure 
there is no sign of cancer cells. The surgeon can perform one of two procedures: 
• Axillary lymph node dissection, in which the surgeon has to remove a number of 
lymph nodes from under the arm and have them examined by a pathologist for 
cancer cells. 
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• Sentinel lymph nodes sampling is a newer procedure in which the surgeon finds 
and remove the sentinel (first) lymph node that receive drainage from the breast 
and examine it for cancer cells. If it is cancer free, research has shown that there is 
a good possibility that the subsequent nodes are free of cancer. To identify the 
sentinel lymph node, the surgeon injects either a dye or a radioactive tracer into 
the area around the person's primary breast tumor. The dye or tracer will travel to 
the lymph nodes, arriving at the sentinel node first. The surgeon can find the node 
when it turns color (if the dye is used) or emits radiation (if the tracer is used) 
[18]. 
Radiation therapy: 
          Radiation is given regularly for a number of weeks following a lumpectomy or 
partial mastectomy in order to eliminate remaining cancer cells near the tumor site. 
Radiation therapy is also recommended for many women after a mastectomy depending 
upon the size of their tumor, number of involved lymph nodes under the arm, and width 
of the margin of resection obtained by the surgeon. Some times radiation is given before 
the surgery to shrink a large tumour and make it easier to remove.  
          Radiation therapy is very effective in reducing the chance of breast returning in 
both the breast and the chest wall. The most common type of radiation used in breast 
cancer is given from a source outside the body and is called external beam radiation 
therapy . Radiation may also be given by pellets implanted in the affected area  
( brachytherapy).  
          Radiation therapy can cause side effects, including fatigue, swelling, and skin 
changes. Most women report a good or excellent long term cosmetic result of their 
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treated breast. A small amount of lung beneath the chest can be treated by the radiation, 
and the risk of pneumonitis, or a radiation related pneumonia, is very rare.  
          In the past with older equipment and techniques of radiation, women treated for left 
sided breast cancers had small increase in the long term risk of heart disease. Modern 
techniques are now able to spare most of the heart from the radiation, so current studies 
generally do not show higher rates of dying from heart disease in women with breast 
cancer treated with radiation compared with women treated without radiation. While 
radiation is thought to be a risk factor of cancer after long periods of time , less than one 
in 500 survivors will develop a different type of cancer , other than a breast cancer , 
within the area that was treated [19]. 
Chemotherapy: 
          Chemotherapy destroys cancer cells that have migrated from the original site of the 
tumor. It may be given orally or intravenously, and is usually given in cycles. 
Chemotherapy generally does not require a hospital stay; women are usually treated in an 
outpatient setting. 
          An oncologist may administer chemotherapy before surgery 
 (neoadjuvant therapy) to shrink a large tumor , or after surgery (Adjuvant therapy). The 
goal is to remove the entire tumor during surgery.  
          Different chemotherapy drugs are useful for different cancers, and research has 
shown that combinations of certain drugs are more effective than individual drugs. Some 
common regimens for breast cancer include combinations of two or three of the 
following chemotherapy drugs: cyclophosphamide, methotrexate, 5 – fluorouracil, 
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doxorubicin, epirubicin, paclitaxel, and docetaxel. Women in clinical trials may be 
offered new drugs or new combinations of existing drugs. 
          Chemotherapy drugs are powerful and affect both healthy and cancerous cells in 
the body. Normal cells that grow quickly, such as those lining the gastrointestinal tract or 
hair follicules, may be damaged or killed along with cancer cells. Side effects can include 
fatigue, nausea, and vomiting, lowered white blood cell count, and a corresponding 
increased risk of infection, mouth sores, hair loss, and premature menopause. Most of 
these side effects go away once treatment is stopped and are not long term [20].  
 Hormonal therapy: 
          Hormonal therapy is useful to manage tumors that test positive for either estrogen 
or progesterone receptors. These tumors use hormones to fuel their growth. Blocking the 
hormones receptor limit the growth of these types of tumors.  
          Tamoxifen is a drug that researchers have studied. It has been shown effective in 
reducing the risk of recurrence in the treated breast, the risk of developing cancer in the 
opposite breast, and the risk of developing cancer in women with no history of the 
disease but who are at higher than average risk of developing breast cancer. Tamoxifen's 
side effects include hot flashes, a small increased risk of uterine cancer, and an increase 
in the risk of blood clots.  
          Newer drugs, such as raloxifene, are showing promise as hormonal agents. They 
may prove  to be as effective as tamoxifen without side effects , but still need to be 
compared in clinical trials . 
          Aromatase inhibitors are emerging as the preferred treatment for women with 
advanced, hormone sensitive cancers. They work by blocking the aromatase enzyme, 
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which is necessary for the production of estrogen. They are also being studied as an 
adjuvant therapy in early breast cancer [21].   
Adjuvant therapy: 
          Adjuvant means ‘‘in addition to ’’ and these therapies are given in addition to 
surgery or surgery plus radiation to decrease the risk of the breast cancer returning. 
Adjuvant therapies include radiation therapy, chemotherapy, and hormonal therapies. 
They are intended to eliminate any breast cancer cells lingering in the body. If it is 
determined that the tumor uses estrogen or progesterone to grow (hormone receptor 
positive), then hormonal treatment may be used alone or together with chemotherapy 
[18]. 
 Immunotherapy: 
          Cancer treatment is enhanced first by understanding, and then utilizing the immune 
system activity. Cancer may develop when the immune system breaks down or is not 
functioning. 
          Treatments such as interferon and colony stimulating factors are used now, either 
alone, or in conjugation with other modalities such as surgery, radiation and 
chemotherapy [22].  
Immunotherapy may be used to: 
• Stop, control, or suppress processes that permit cancer growth. 
• Make cancer cells more recognizable, and therefore more susceptible to 
destruction by the immune system. 
• Boost the killing power of the immune system cells, such as T- cells, NK – cells 
and macrophages. 
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• Alter cancer cells' growth patterns to promote behavior like that of healthy cells. 
• Block or reverse the processes that changes a normal cell or a precancerous cell 
into a cancerous cell. 
• Prevent breast cancer cells from spreading to other parts of the body [23].  
1.5 Breast cancer antigens: 
Breast cancer tissues are characterized by over expression of normal antigens, down 
regulated antigens and presence of new antigens which are not found in normal tissues.  
Over expressed antigens: 
Some breast cancer tissues are characterized by over expression of specific antigens like 
estrogen receptor,  progesterone receptors, Her2/new [24],  HMGA1 ( High Mobility 
Group AT- hook 1 ) antigen [25], VEGF (Vascular Endothelial Growth Factor)[26]. 
Estrogen Receptor: 
Estrogen receptor refers to a group of receptors that are activated by the estrogen 
hormone [27]. Two types of estrogen receptor exist: ER which is a member of the nuclear 
hormone family of intracellular receptors and the estrogen G protein coupled receptor 
GPR30 (GPER), which is a G-protein coupled receptor. The estrogen receptor that is 
involved in the breast cancer is the ER type [27].The main function of the estrogen 
receptor is as a DNA binding transcription factor that regulates gene expression. 
However, the estrogen receptor has additional functions independent of DNA binding 
[28].  
Estrogen receptors are over-expressed in around 70% of breast cancer cases, referred to 
as ER positive. Two hypotheses have been proposed to explain why this causes 
tumorigenesis, and the available evidence suggests that both mechanisms contribute: 
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Firstly, binding of estrogen to the ER stimulates proliferation of mammary cells, with the 
resulting increase in cell division and DNA replication leading to mutations. Secondly, 
estrogen metabolism produces genotoxic waste. The result of both processes is disruption 
of cell cycle, apoptosis and DNA repair and therefore tumor formation [29].                                                     
There are two types of ER,  ERα is certainly associated with more differentiated tumors, 
while evidence that ERβ is involved is controversial. Different versions of the ESR1 gene 
have been identified (with single-nucleotide polymorphisms) and are associated with 
different risks of developing breast cancer [30].                        
Progesterone Receptors:   
The progesterone receptor (PR) also known as NR3C3 (nuclear receptor subfamily 3, 
group C, member 3), is an intracellular steroid receptor that specifically binds 
progesterone [31]. It has two main forms, A and B, that differ in their molecular weight 
and mode of action. PR A antagonize the action of estrogen by inhibiting the epithelial 
cells proliferation, while the PR B contributes to epithelial cells proliferation in presence 
or absence of estrogen [32]. It is well known that progesterone receptors are elevated in 
most of ER+ breast cancer patients [33]. 
 HER-2/neu: 
HER2/neu (also known as ErbB-2, ERBB2) stands for "Human Epidermal growth factor 
Receptor 2" [34]. HER2 is a cell membrane surface-bound receptor tyrosine kinase and is 
normally involved in the signal transduction pathways leading to cell growth and 
differentiation [35]. HER-2/neu is found in abundance in about 30% of breast cancers and 
is most likely directly related to uncontrolled cancer growth. It has been studied as an 
immune target in breast cancer [36]. 
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High Mobility Group Protein (HMG):  
HMG is a protein encoded by High mobility group AT-hook 1 (HMGA1) gene [37]. 
It is a non-histone protein involved in many cellular processes, including regulation of 
inducible gene transcription, integration of retroviruses into chromosomes, and the 
metastatic progression of cancer cells including breast cancer cells [38-39].     
Down regulated antigens: 
Claudins (CLDN) 
Claudins are a family of proteins that are the most important components of the tight 
junctions [40]. Claudins are 24 small transmembrane proteins. They are very similar in 
their structure, although this conservation is not observed on the genetic level [41]. The 
major function of the claudins is to control the paracellular transport and signal 
transduction [42]. Some of the claudins are down regulated in breast cancer including 
CLDN 1, 4 and 7 [43].   
Abnormal antigens:  
Some breast cancer tissues present abnormal antigens, which are not presented in the 
normal breast tissues, some of them are well studied, while others stay not well studied  
[44].  
14C5 antigen:  
          14C5 antigen is one of the well studied abnormal antigens in breast ductal 
carcinoma. 14C5 antigen plays a role in substrate adhesion and subsequently also in 
invasion of breast cancer cells .The 14C5 antigen is a protein composed of two 
polypeptide chains with molecular weight of 50 and 90 kd.  
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          14C5 monoclonal antibodies are produced and they are able to inhibit cell substrate 
adhesion and invasion in vitro of breast cancer cells [45].  
Oncofetal Antigen (OFA ) :  
          Oncofetal antigen (OFA) is 44 KDa glycoprotein expressed during early to mid 
gestation fetal development and re-expressed as a surface antigen by tumor cells soon 
after transformation . The antigen is detectable on all types of human tumors tested , but 
it is undetectable on normal cells [46]. 
UDP-N-acetyl-D-galactosamine- polypeptide N-acetylgalactosaminyl transferases 
(ppGalNAc-T6 ) : 
ppGalNAc-T6 is a transferase enzyme responsible for the transfer of GalNAc from UDP- 
GalNAc to normal cellular proteins (mucins). Addition of the GalNAc to the normal 
protein activates sequential addition of glucose residues by glycosyltransferases, which 
also participate in changing the normal cellular antigen structure. ppGalNAc-T6 is 
present in breast cancer tissues and is sporadically found in non malignant breast diseases 
(sclerosing adenosis and fibroadenoma with focal hyperplasia), while it is totally absent 
from normal breast tissues. The presence of this enzyme in the cancerous breast tissues 
leads to the glycosylation of normal structural proteins and so production of many 
abnormal antigenic structures in breast cancer tissues [47].  
Targeting immune response to glycosylated proteins (mucins) by ppGalNAc-T6 represent 
a promising approach for development of therapeutic vaccines against cancers [47]. 
Survivin: 
Human survivin is a cytoplasmic protein, with a molecular weight of 16.5kDa. It consists 
of 142amino acids, and its gene is located on chromosome 17[48]. Survivin is a unique 
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inhibitor of apoptosis usually expressed in the embryonic lung and fetal organs in the 
developmental stages but undetectable in normal adult tissues. However, survivin seems 
to be selectively expressed in transformed cells and in most human cancers, including 
breast cancer [49].   
1.6 Monoclonal antibodies and their importance in breast cancer diagnosis and    
      treatment: 
Monoclonal antibodies (mAb) are monospecific antibodies that are identical because they 
are produced by one type of a single parent immune cell. Given almost any substance, it 
is possible to create monoclonal antibodies that specifically bind to that substance; they 
can then serve to detect or purify that substance [50].   
The monoclonal antibodies are produced by the hybridoma technique, which involves 
fusion of a plasma cell with a myeloma cell  to produce a hybridoma cell  using poly 
ethelene glycol (PEG) as a fusing agent and Hypozanthin Aminoptern Thymidine (HAT) 
medium as selective media. The HAT media permits hybridoma cells to grow, while 
inhibiting myeloma cells and plasma cells.  
The HAT media inhibits the DNA synthesis salvage pathway through inhibiting the 
Hypoxanthine Guanine Phosphoribosyle transferase enzyme (HGPRT). The myelooma 
cells lack the denovo DNA synthesis and depend totally on the salvage pathway; thus the 
myeloma cells are not capable of growing in HAT medium. The denovo and the salvage 
pathways of DNA synthesis are active in the plasma cells; the HAT media can not kill the 
plasma cells. However the life span of the plasma cells is short. Only the hybridoma cells 
can grow in the HAT media because they posses the denovo pathway from the plasma 
cells and the unlimited life span from the myeloma cells [51].  
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         The hybridoma cells posses the functions of the plasma and myeloma cells; 
production of antibody and rapid, unlimitted division respectively. The hybridoma cells 
are cloned to obtain a hybridoma cell line which originated from one cell. There are 
different techniques to prepare a hybridoma cell line originated from one cell .e.g. 
limiting dilution growing in soft agar cloning and flow cytometry [52].   
        Once monoclonal antibodies for a given substance have been produced, they can be 
used to detect the presence of this substance. The Western blot test and immuno dot blot 
tests detect the protein on a membrane. They are also very useful in 
immunohistochemistry which detect antigen in fixed tissue sections, immunofluorescence 
test which detect the substance in a frozen tissue section or in live cells and 
immunoassays [50].     
          The use of monoclonal antibodies is one way to fight breast cancer, since they can 
be directed against antigens located on the surface of tumor cells. Trastuzumab and 
bevacizumab are the examples of the use of monoclonal antibodies in the treatment of 
breast cancer [53]. 
          The monoclonal antibodies can be used either alone to kill cancer cells, or as 
carriers of other substances used either for treatment or diagnostic purposes. For example, 
chemotherapeutic agents can be attached to monoclonal antibodies to deliver high 
concentrations of these toxic substances directly to the tumor cells. In theory, this 
approach is less toxic and more effective than conventional chemotherapy because it 
reduces the delivery of harmful agents to normal tissues [54].  
          During the diagnostic process, monoclonal antibodies can be used to carry 
radioactive substances to cancer cells within the body, thus pinpointing the location of 
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metastases that were previously undetected by other methods. Satoh T and his colleagues 
used  rdio labeled monoclonal antibodies against the Carcinoembryonic Antigen (CEA) 
to detect metastasis of colorectal cancer [55]. 
1.7 Objectives:  
General objectives:  
         To identify and characterize abnormal antigens in cancerous breast tissues in 
comparison to normal breast tissues. 
Specific objectives:  
      1- Determine the identified abnormal antigens molecular weight, pI and orders 
2- Extract one of the abnormal antigens. 
3- Produce monoclonal antibodies against the extracted abnormal antigen.  
1.8 Rationale: 
          This study is directed towards extraction and characterization of a new abnormal 
antigen in breast cancer tissues from Sudanese patients so as to cope with the 
international efforts to study the abnormal antigens which can, in the future, lead to new 
effective cancer therapies. The ultimate goal is to control the breast cancer by production 
of effective vaccine. Another aim of this study is to produce monoclonal antibodies 
against the extracted abnormal antigen which can be used in the early diagnosis and 
treatment of breast cancer. Also this study can participate in the transfer of the proteomic 
techniques to the Sudan, which lead to the development of the Sudan in the area of 
proteomic research.   
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CHAPTER TWO 
Material and Methods 
The study area and population 
This study was done within the period of October 2006 to June 2008. Samples were 
collected from Khartoum Teaching Hospital, Elengaz Surgical complex and Ibrahim 
Malik Teaching Hospital. All the hospitals are located in Khartoum locality of Khartoum 
state. Breast tissue samples were obtained from 120 patients after informed consent, 
diagnosed clinically as breast cancer patients and confirmed by Fine Needle Aspiration 
Cytology (FNAC). Two tissue samples were obtained from each patient, one from the 
normal tissue and the other from the cancerous tissue. The samples were confirmed by a 
histopathologist according to Bloom Richardson’s grading system. All patients were at 
early stage with neither nodal involvement nor metastasis to any other organs . Tissue 
samples were directly transferred to liquid nitrogen and stored.  
Sample preparation 
Tissue samples were crushed using liquid nitrogen cooled mortar and pestle. Proteins 
were extracted using SIGMA  ProteoPrep® sample extraction kit (PROTTOT- 1KT) 
according to manufacturer instructions (Annex 1).The protein concentration was 
determined using BioSystems modified Bradford protein assay kit using Bovine Serum 
Albumin (BSA) as standard . The supernatant was kept at -70˚C refrigerator.  
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Two Dimensional Poly Acrylamide Gel Electrophoresis (2D PAGE) 
450 µg of each sample were loaded on 10cm pharmalyte pH gradient strips pH 3-10, 
which are prepared locally in capillary tubes (Labnet, cat. No. E2110- 2D- CT, USA). 
Also some samples were loaded on 18cm Immobiline pH gradient strips (Amersham IPG, 
pH 3-10, 18 cm, UK). The two types of loaded strips were rehydrated for 12 hours at 
room temperature. Isoelectric Focusing was performed with 50µA per strip at 20°C with 
4 step voltage modes, Step and Hold (500V, 0.5 kV/ h), gradient (1000 V, 0.8 kV/ h), 
gradient (8000 V, 13.5 kV/ h) and step and hold (8000 V, 12.2 kV/h).   
Separation of the second dimension was performed in 12% SDS/ polyacrylamide gels  
(10x10 cm and 20x20cm) using the Enduro 2D PAGE system (Labnet, USA) and 
Multiphore™ (Amersham, UK) respectively. Proteins in the analytical gels were stained 
with Coomassie stain. The results of the locally produced strips and the amersham strips 
were comparable. The Coomassie stain was prepared using Coomassie Brilliant Blue G-
250 stock following the manufacturer’s protocol.  .  
The stained gels were examined by image scanner II (Amersham, UK) using LabScan5 
software (Amersham, UK). Certain defined spots were digested by Trypsin enzyme using 
Ettan™ spot handling workstation (Amersham, UK) for identification and one spot was 
used for monoclonal antibody production. 
Liquid Chromatography Mass Spectroscopy (LC/MS) and protein identification 
A total of 5µl of protein digest were loaded onto a reversed-phase(RP) C18 column for 
LC/MS analysis . The HPLC system used was Finnigan Surveyor™ MS pump with a 
flow splitter, column 0.18×100 mm C18 (Thermo Electron, USA ) and flow rate of 
200µl/min while the mobile phases were A: water with 0.1% formic Acid and B : 
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acetonitrile with 0.1%formic acid and gradients were 2-60% B in 20 min , 65-80 % B in 
5 min , hold 5 min and 80-2% B in 2 min. LC/MS used was Finnigan LTQ linear ion trap 
mass spectrometer (Thermo Electron, USA) and the conditions  were as follows : 
ionization mode was nanospray, positive ion, 200° C capillary temperature, 1.8 KV spray 
needle voltage, 400-1.600 m/z Mass range. Scan sequence was Full-scan mass 
spectrometry and Acquisition modes were normal, data dependent and dynamic 
exclusion. 
          Protein identification was performed using the Turbo SEQUEST algorithm in the 
BioWorksTM3.1SR1 software package (Thermo Electron, USA) and nr.fasta database 
 ( www.ionsource.com ).  
Hybridoma technique  
          The spot of the interest was solublized in 1ml of 0.5M phosphate buffered saline 
and the protein concentration was determined using the BioSystem modified Bradford 
assay. 30 µg of the antigen was dissolved in 0.5ml Freund’s Complete Adjuvant (FCA) 
and injected subcutaneously in multi sites of  2 Balb/C mice.   
After 3 weeks intervals the mice, again, were injected subcutaneously in multi sites with 
30 µg of the antigen in 0.5ml Freund’s Incomplete Adjuvant (FIA) and tested for 
antibodies.  
Test for antibodies  
          The mouse was wormed to dilate the tail vein. The tail vein was punctured with 
sterile hypodermic needle and the blood was absorbed onto a filter paper to form a blood 
spot. The blood spot was punched into a test tube and eluted in 150 µl ELISA assay 
buffer, this gives approximately 50 times dilution. The diluted blood spot was serially 
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diluted to set a titration curve then tested for antibody using Enzyme Linked Immuno 
Sorbent Assay (ELISA). Five 96 well ELISA plates and 100 polystyrene test tubes were 
coated with 100 µl of beta-tropomyosin spot with a concentration of 5 µg/ml, incubated 
overnight at 4˚C.For the detection of antibody sensitivity 50 polystyrene test tubes were 
coated with casein and bovine serum albumin (BSA).100µl of the harvested blood was 
added to some the coated polystyrene test tubes and incubated for one hour at 37˚C. Then 
100µl of rabbit anti mouse IgG bound to alkaline phosphatase and incubated for one hour 
at 37˚C. After the incubation period substrate was added (picric acid) and the absorbance 
was measured at 405nm. The coated ELISA plates were used in the cloning step. 
Fusion and cloning  
          The mouse with highly positive ELISA test was sacrificed and the spleen was 
taken out and a cell suspension was made to 50×106 total number of cells. Myeloma (sp2) 
cell line was donated from the SAEC and was grown to 50×106 total number of cells with 
90% viability. The count and the viability of cells were determined using inverted 
microscope and 0.4% trypan blue staining. 
          The immunized spleen lymphocytes and the myeloma cells were mixed and 
centrifuged at 800g for 5 minutes. 0.8 ml of PEG were added slowly over one minute 
with gentle mixing at 37˚C, then mixed for 90 seconds, diluted with 10ml RPMI 1640 
over 5 minutes, centrifuged at 800g for 5 minutes, resuspended in 10mls culture flask in 
complete medium which contained 20% fetal calf serum and incubated overnight at 
37°C. In the second day, 5mls were removed from the culture flask and 5mls of 2x 
Hypoxanthine Aminopterin Thymidine (HAT) was added. The dilution process was 
repeated on day 4, 6, 8, 10.and 12. ELISA screening tests were done at day 4, 8 and 12.  
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After day 12 and by the day 18 the hybridoma cells in the culture flask were transferred 
to complete medium.   
          Regarding the cloning step, the number of hybridoma cells in the culture flask was 
counted and the viability was adjusted at 90%. The hybridoma cells were diluted to 
obtain a final concentration of 10cells per ml (one cell per every 100 µl). 10ml of the 
diluted hybridoma cells were distributed into one culture plate of 96 wells and incubated 
at 37˚C. The incubated cells were followed daily and tested for antibody every four days. 
The positive wells from one cell were transferred to 24 well culture plate, incubated at 
37˚C and growth was followed and tested. Positive wells were transferred to 6 well 
culture plates, followed and tested. From the 6 well culture plates, the positive wells were 
transferred to 10ml culture flask, then to 35ml culture flasks. The cells of 35ml culture 
flask were frozen after addition of Di Methyle Sulpho Oxide (DMSO) in 2 cryo tube . 
Each cryo tube contained 5 million hybridoma cells, 0.5ml DMSO and 0.5ml cells 
mixture. The two crytubes were firstly transferred to -20˚C refrigerator for one day then 
transferred to -70˚C refrigerator for 24 hours and finally to liquid nitrogen.     
Antibody harvest and purification   
          The cells of the 35ml culture flasks were centrifuged at 2000g for 15minutes, the 
cells were re suspended in 30ml RPMI medium and the supernatant (antibody containing) 
was kept frozen. The monoclonal antibody was purified following SIGMA antibody 
purification kit protocol (Annex 2). PAGE (the same method as described above 
excluding the isoelectric focusing step) was done for the purified monoclonal antibodies 
so as to determine the molecular weight and to check the purity. ELISA tests for the 
purpose of determining the specificity were done using the casein and BSA coated tubes. 
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All the monoclonal antibodies production methods were extracted from the practical 
guide of monoclonal antibody production prepared by  Eryl Liddell and A Cryer [56]. 
Statistical analysis 
          The general information of the patients was analyzed using the Statistical Package 
for the Social Sciences computer program (SPSS) version 16.  
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CHAPTER THREE 
Results 
          The total number of the patients involved in this study was 120 female patients. 
The mean age of the patients was 47.2 ( 16 to 80 ). Two age groups were with equal, 
highest, incidence rate (≥ 44) and (45-64) and the Khartoum state had the highest 
incidence rate (Table.1). 
          Depending on the histopathology reports, the tissue samples were diagnosed as 
invasive ductal and lobular carcinomas with three grades. Most of the patients (112, 
93.3%) were diagnosed as invasive ductal carcinoma, while 8 patients (6.7%) were 
diagnosed as lobular carcinoma (Table.2). 
2D PAGE results: 
          Three different patterns of 2D PAGE results were obtained. In the first 2D result 
four abnormal antigens were detected in the cancerous breast tissues and undetected in 
the normal breast tissues of the same patient. The number of patients with the first 2D 
result were 32 patients (26.7% of all patients) (Fig.1 and Fig.4).  
          The second 2D result reflected that the cancerous and normal breast tissues of 81 
patients (67.5 % of all patients) were the same; there was no abnormal antigens in the 
cancerous breast tissues (Fig.2 and Fig.4).  
          The last 2D result involves presence of two abnormal antigens of the first 2DPAGE 
result. Seven patients (5.8% of all patients) carried the last 2D result pattern  
(Fig.3 and Fig.4).  
          All the normal breast tissues of all patients were missing all the four abnormal 
antigens (Fig.4). 
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Table.1 Age groups and geographical distribution of the patients with breast      
                cancer. 
 Geographical distribution of patients Age groups (years) 
Khartoum 
state 
Central 
states 
Northern 
states 
Western 
states 
Eastern 
states 
≥ 44 
 
45-64 ≤ 65 
No of 
patients 
61 19 13 15 12 49 50 21 
Total 120 120 
Mean 
age 
47.2 
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Table.2 Types and grades of breast cancer among the Sudanese patients. 
Type of cancer Ductal carcinoma Lobular carcinoma 
Grade I II III I II III 
Number of patients 28 51 33 4 3 1 
Total 112 8 
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          *control is Fig.4  
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Identification of the abnormal antigens: 
LC/MS results: 
          Each trypsin digestion products of each spot were introduced in the LC/MS 
machine. For each digestion site a spectrum was generated and the amino acid sequence 
of the digestion product was determined by the soft ware attached to the machine.  
Spot 1: 
          In spot 1, there were two trypsin digestion sites, i, e there were two poly peptides 
produced by the action of the enzyme. The precursor mass of the first digestion site was 
604.26 and its amino acid sequence was CMPTFQFF (Fig.5), While the precursor mass 
of the second digestion product was 612.35 and its amino acid sequence was 
CM*PTFQFF (Fig.6). 
Spot 2: 
          Spot 2 digestion produced two polypeptides and two spectra were generated, the 
first one of precursor mass 824.96 and amino acid sequence of FNAHGDANTIVCNS 
(Fig.7) and the second polypeptide was of precursor mass 893.92 and amino acid 
sequence of LNLEAINYMAADGDF (Fig.8). 
Spot 3: 
          In spot 3, also, two poly peptides were obtained by the action of the trypsin. The 
polypeptide was with a precursor mass of 732.04 and had the amino acid sequence of 
CTKEEHLCTQ (Fig.9). The second polypeptide was with a molecular weight of 973.45 
and had the amino acid sequence of ALKDEEKMELQELQL (Fig.10).  
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Spot 4:  
          Spot 4 was digested by trypsin and three polypeptide fragments were produced. 
The poly peptide was with a precursor mass of 673.19 and amino acid sequence of 
QLEEEQQALQ (Fig.11) The precursor mass of the second polypeptide was 801.49 and 
it amino acid sequence was GTEDEVEKYSESV (Fig.12). The third digest product 
molecular weight was 817.3 with amino acid sequence of CKQLEEEQQALQ (Fig.13).  
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Fig.5  Spectrum of  the trypsin digest  of precursor mass 604.26 and its amino acid     
            Sequence of spot 1. 
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Fig.6  Spectrum of  the trypsin digest  of precursor mass 612.35 and its amino acid     
            Sequence of spot 1. 
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Fig.7 Spectrum of  the trypsin digest  of precursor mass 824.96 and its amino acid     
            Sequence of spot 2. 
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Fig.8 Spectrum of  the trypsin digest  of precursor mass 893.92 and its amino acid     
            Sequence of spot 2.  
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Fig.9 Spectrum of  the trypsin digest  of precursor mass 732.04 and its amino acid     
            Sequence of spot 3.  
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Fig.10 Spectrum of  the trypsin digest  of precursor mass 973.45 and its amino acid     
            Sequence of spot 3.  
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Fig.11 Spectrum of  the trypsin digest  of precursor mass 673.19 and its amino acid     
            Sequence of spot 4.  
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Fig.12 Spectrum of  the trypsin digest  of precursor mass 801.49 and its amino acid     
            Sequence of spot 4.  
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Fig.13 Spectrum of  the trypsin digest  of precursor mass 817.30 and its amino acid     
            Sequence of spot 4.  
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nr.fasta and Protein Databases search results: 
     By inserting the spectra of each spot in the  nr.fasta database the spots were identified 
as: Spot 1 was human Thioredoxin (D60n mutant), with 105 amino acids, the average 
mass of 11737.5 Da and the Isoelectric point (pI) was 4.95 (Fig.14). The secondary 
structure elements (SSE) were obtained from the PDB (Fig.15). However the tertiary 
structure is not mentioned in the PDB. Spot 1 was detected in 39 patients.  
       Spot 2 was X-ray crystal structure of human galectin-1, with 134 amino acids, 
average mass of 14595.4 Da and the pI was 5.34 (Fig.16). The SSE were shown in 
(Fig.17), also the tertiary structure of  X-ray crystal structure of human galectin-1 is not 
mentioned. Spot 2 was detected in the cancerous tissues of 39 patients. 
         Spot 3 was rcTPM3 (retro copy of tropomyosin 3), with 247 amino acids, average 
mass of 28824.2 Da and pI of 4.77 (Fig.18).The tertiary structure of rcTPM3 was 
obtained from the SWISSPROT database (Fig.19). Spot 3 was detected in the cancerous 
tissues of 32 patients. 
          Spot 4 was identified as beta-tropomyosin (Iso form 2). Bet-tropomyosin was 
composed of 257 amino acids with average molecular weight of 29942.3 Da and pI of 
4.70 ( Fig.20 ). The tertiary structure of beta-tropomyosin is shown in (Fig.21), it was 
obtained from the SWISSPROT database. Spot 4 was detected in the cancerous tissues of 
32 patients. 
          All the protein identities including their names, swissprot database accession 
numbers, molecular weights, isoelectric points, the percentages of the trypsin digest 
masses of each protein total mass and the ideal number of peptides of each trypsin 
digestion products as tabulated in the ne.fasta database were shown in [Table.3]. 
48 
 
Fig.14 nr.fasta database search result of spot 1. 
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Fig.15 Secondary structure elements of human thioredoxin (D60n mutant) 
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Fig.16 nr.fasta database search result of spot 2. 
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Fig.17 Secondary structure elements of X-ray crystal structure of human  
            galectin-1. 
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Fig.18 nr.fasta database search result of spot 3. 
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Fig.19 The tertiary structure of rcTPM3. 
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Fig.20 nr.fasta database search result of spot 4. 
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Fig.21 The tertiary structure of beta-tropomyosin. 
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Table.3 Identities and peptide masses of the abnormal antigens 
Spot 
no.  
Protein name  Swiss-prot 
accession 
no.  
Mr ( Da )  pI  Coverage 
By mass  
Matched 
peptides  
no.  
1  Thioredoxin D60n 
mutant  
P10599  11737.5  4.95  32.80%  1 out of 2  
2  X-ray crystal 
structure of human 
galectin-1  
P09382  14595.4  5.34  68.48%  2 out of 8  
3  rcTPM3 ( Fragment )  Q2QD06  28824.2  4.77  23.76%  2 out of 6  
4  Beta-tropomyosin  
( isoform 2 )  
P07951  29942.3  4.70  18.85%  3 out of 5  
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Results of monoclonal antibody production. 
          Two mice were immunized with beta-tropomyosin-like spot red colour lable 
marked and green colour lable marked mice (Annex.3 and Annex.4). One mouse is not 
immunized and is marked with white colour lable as a control mouse (Annex.5). 
The green colour lable marked mouse had the highest response, the blood sample give a 
positive result up to 516000 time dilution (516000 titer) [Table.4], so it was sacrificed  
 and its spleen was removed (Annex.6). The red colour labled mouse was saved. 
The spleen cells were scratched and fused with the sp2 myeloma cell line and cultured in 
10ml culture flask. ELISA tests were done to test production of antibodies on day 4, day 
8 and day 12. The absorbance was increasing from 0.49 to 0.57 and finally the 
absorbance was 0.74. The total number of hybridoma cells was counted and it was  
4.5× 106 cell. The viability was 90%. In order to do the cloning, by the limiting dilution 
method, 10ml of hybridoma cells with a concentration of 10cells/ml (one cell/ 100µl) was 
prepared and distributed in 96well culture plate, 100µl per each well.  
The 96 well cell culture plate was tested for antibody productivity using ELISA plate. 
Two tests were done to follow the production of antibody and to decide which well 
should be expanded to obtain a cell line originated from one cell per well. 
The first ELISA assay test was done after 4 days of cloning. 6 wells were found 
containing one cell and they were producing antibody A12, B11, F3, G11, H4 and H9 
 [Table.5].The second ELISA assay test was done 8 days after cloning. By comparing 
ELISA tests, it was clear that only B11 and G11 were increasing their antibody 
productivity while the productivity in the other wells was decreasing [Table.6].   
Depending on the two ELISA results, a decision was taken to expand B11 and G11.   
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The expansion of B11 was failed due to contamination. G11 was expanded to 24 well 
culture plate, 6 well culture plate, 10ml culture flask and finally to 35ml culture flask. 
The antibody harvested and finally the G11 cell line was frozen with Di Methyl Sulpho 
Oxide (DMSO) in -20ºC, -70 ºC refrigerators and finally in liquid nitrogen.  
The harvested antibody was purified and the final antibody concentration was 0.35mg/ml      
and the volume of the harvest was 25 ml. Specificity ELISA tests were negative when 
casein and BSA coated tubes were used. The PAGE results has shown single band for the 
monoclonal antibody with a molecular weight approximately equivalent to 30 KDa 
[Fig.22].          
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Table.4: Mice Immunization results: 
 
 
1/1k 1/2k 1/4k 1/8k 1/16k 1/32k 1/64k 1/128k 1/256k 1/516k 
Green 
 
+ + + + + + + + + + 
Control 
 
+ + - - - - - - - - 
Red 
 
+ + + + + + - - - - 
K ≡ 1000  
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Table.5 First after cloning ELISA assay test results (Absorbance at 405nm). 
 A B C D E F G H 
1 0.345 0.339 0.367 0.345 0.333 0.336 0.311 0.338 
2 0.302 0.328 0.329 0.346 0.315 0.347 0.321 0.514 
3 0.313 0.402 0.393 0.392 0.395 0.537 0.369 0.405 
4 0.364 0.350 0.416 0.421 0.405 0.392 0.423 0.473 
5 0.384 0.441 0.465 0.450 0.429 0.417 0.420 0.614 
6 0.382 0.396 0.387 0.379 0.403 0.382 0.394 0.446 
7 0.372 0.443 0.450 0.450 0.434 0.421 0.382 0.679 
8 0.380 0.395 0.398 0.444 0.389 0.387 0.416 0.598 
9 0.381 0.464 0.461 0.446 0.420 0.425 0.421 0.750 
10 0.374 0.392 0.619 0.390 0.397 0.421 0.407 0.633 
11 0.385 0.425 0.442 0.412 0.411 0.400 0.451 0.488 
12 0.498 0.380 0.372 0.386 0.381 0.363 0.406 0.562 
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Table.6 Second after cloning ELISA assay test results (Absorbance at 405nm). 
 A B C D E F G H 
1 0.339 0.338 0.366 0.345 0.367 0.345 0.314 0.365 
2 0.332 0.389 0.308 0.346 0.310 0.389 0.325 0.497 
3 0.313 0.423 0.384 0.392 0.398 0.337 0.343 0.413 
4 0.354 0.357 0.400 0.421 0.445 0.399 0.427 0.477 
5 0.326 0.444 0.453 0.450 0.456 0.467 0.428 0.563 
6 0.380 0.398 0.377 0.379 0.390 0.388 0.392 0.440 
7 0.377 0.432 0.670 0.450 0.454 0.420 0.376 0.497 
8 0.375 0.384 0.387 0.444 0.380 0.345 0.409 0.399 
9 0.389 0.398 0.468 0.446 0.427 0.487 0.497 0.601 
10 0.374 0.376 0.469 0.390 0.386 0.483 0.465 0.543 
11 0.380 0.645 0.449 0.412 0.411 0.434 0.731 0.489 
12 0.340 0.389 0.386 0.386 0.381 0.360 0.443 0.465 
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Fig.4  PAGE result for the purified anti beta-tropomyosin monoclonal antibody 
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CHAPTER FOUR 
Discussion 
The general description of the patients can not be compared to the local, regional or 
international data, because the number of patients is limited. However, this study showed 
that the mean age group of having breast cancer was 47.2 compared to 40 in USA and 
Europe [57- 2]. The most affected age groups by breast cancer were 0-44 and 45-64, this 
finding is, to some extent, similar to the international data [2]. Most of the patients were 
diagnosed as invasive ductal carcinoma (93.3%), while the international findings show 
that the ductal carcinomas represent approximately 70% of the breast cancers [58]. 
Khartoum state was the most affected area; this is because Khartoum is capital of Sudan 
and all the quality services are located in it. 
           This study detected four abnormal proteins in the cancerous breast tissues and they 
were absent from the normal tissues of the same patients. Two of them were synthetic 
proteins, synthesized by X-ray crystallography; they are not expected to be found in 
human tissues. They were thioredoxin (D60n mutant) and X-ray crystal structure of 
human galectin-1. The other two abnormal proteins were rcTPM3 and the isoform2 of 
beta-tropomyosin. 
Human Thioredoxin (D60n mutant): 
          This study detected the presence of the thioredoxin (D60n mutant) in 32.5% from 
the study population. The thioredoxin (D60n mutant) is a synthetic protein synthesized by 
X-ray crystallography for the native thioredoxin. The thioredoxin (D60n mutant) is 
characterized by replacement of Aspartate 60 to Asparagine. This mutation causes the 
dimerization of the thioredoxin. The dimer is stabilized by disulphide bonds between 
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cysteine residues [59].  However, thioredoxins are a family of small redox proteins that 
share a highly conserved Trp-Cys-Gly-Pro-Cys-Lys active site [60].The active site 
cysteines of thioredoxins undergo reversible oxidation and reduction catalyzed by 
thioredoxin reductase, an enzyme that use NADPH as its source of reducing equivalents 
[61-62]. Human thiredoxin can be exported out of the cell where it has additional 
functions, including the ability to stimulate normal and cancer cell growth [59]. 
Thioredoxins has been shown to play a major role in a variety of human diseases like 
diabetes mellitus, goiter and cancer. Over expression of  thioredoxin protect cancer cells 
from spontaneous and drug induced apoptosis. Clinically thioredoxin is over expressed in 
a number of human primary tumors where it is associated with increased cell 
proliferation, decreased apoptosis and decreased patient survival. In contrast cells 
expressing the inactive thioredoxin mutant are more sensitive to spontaneous and drug 
induced apoptosis [63]. Cells stably transfected with a redox inactive thioredoxin mutant 
showed decreased cell growth, decreased colony formation in soft agar and inhibited 
tumor formation in vivo [64]. Presence of the thioredoxin (D60n mutant) is not an artifact 
because it is not detected in the normal tissues of the same patients beside that the 
cancerous and normal tissues were treated equally. The presence of this synthetic protein 
in cancerous tissues can be due to X-ray investigation which is a routine investigation, 
environmental factor like the UV of the sun light or it can be a compensation mechanism 
of the human bodies to resist breast cancer since the elevation of the normal thioredoxin 
leads to drug and apoptosis resistance in breast cancer.  
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Galectin-1 and  X-ray crystal structure of human galectin-1: 
          Galectin-1 (gal-1), a member of the mammalian beta-galactoside binding proteins, 
preferentially recognizes Galbeta1- 4GlcNAc (LacNAc) sequences of oligosaccharides 
associated with several cell surface glycoconjugates [65].Galectin-1 exist as a homodimer 
and can facilitate intramolecular and intermolecular cross bridging. Such cross bridging 
may facilitate cellular signaling through growth factor receptors, or mediate cell- cell 
adhesion [66].Galectin-1 is up regulated in several cancers and its expression is often 
higher in more differentiated tumors [67-69].  High level expression of galectin-1 is 
found in lymphatic organs, which feature high rate of apoptosis. Further more, it is 
known that galectin-1 can initiate T cell apoptosis [65]. Other studies concluded that 
galectin-1 is a negative growth regulator for certain types of tumors and activated T cell 
[70]. X-ray crystal structure of human galectin- 1 is synthesized by X-ray 
crystallography, amino acid number 16 is converted to unknown amino acid (X).The X-
ray induced single site mutation revealed the presence of many alterations in the wild 
type (galectin-1) conformation and function [70]. The mutant galectin-1 has no capability 
to undergo the induction of apoptosis and the negative regulation of cell growth leading 
to the clinical picture complications of the cancer patients. However, this study detected 
this mutated protein in 32.5% of the study population. The presence of this mutated 
protein is not due to an artifact. It can be due to nuclear techniques investigations or any 
other environmental factor.  
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The retro copy of tropomyosin 3 (rcTPM3): 
          This study reported the detection of rcTPM3 in 26.7% 0f the study population 
cancerous tissues. rcTPM3 is a retro copy of tropomyosin3, which is produced by a 
mechanism known as retro positioning. Retro positioning is a mechanism responsible for 
generating new intronless gene copies (retrocopies) by reverse transcription of mRNAs 
derived from source genes (parental genes), followed by reintegration of the resulting 
gene in the genome [71]. Retro position was commonly thought to generate non 
functional gene copies that accumulate disablement such as premature stop codons and 
frame shift mutations [72]. Some studies have shown that retroposition has generated a 
significant number of new functional genes (retro genes) in mammalian and invertebrate 
animals genomes [73]. Detection of rcTPM3 in the cancerous tissues may be due to HIV 
infection or MMTV infection, since the gene is obtained by reverstranscriptase. There is 
some evidence showing the correlation between HIV and MMTV infection and breast 
cancer incidence [74-77].   
Beta-tropomyosin (isoform 2): 
         There are three isoforms of beta -tropomyosin; isoform 1 with 284 amino acids 
[78], isoform 2 with 284 amino acids [79] and isoform 3 with 248 amino acids [80]. Beta-
tropomyosin binds to actin filaments in muscle and non muscle cells. It plays a central 
role in association with the troponin complex, in the calcium dependant regulation of 
vertebrate striated muscle contraction. In non muscle cells, beta-tropomyosin is 
implicated in stabilizing cytoskeleton actin filaments [81]. There are two diseases 
associated with defects in beta-tropomyosin, Nemaline Myopathy type 4 (NEM4) and the 
distal arthrogryoposis type 1(DA 1). NEM4  is a form of congenital myopathy 
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characterized by abnormal thread or rod like structures in muscle fibers on histology [82]. 
DA 1 is a form of inherited multiple congenital contractures [83]. Up regulation of 
tropomyosin isoform 2 was previously reported in highly metastatic breast cancer cell 
lines [84]. Down regulation of the beta- tropomyosin isoforms expression has been 
reported previously in primary breast carcinoma cell lines [85] and in primary breast 
tumors [86]. The tropomyosin alpha forms were detected in normal human mammary 
epithelial cell lines [86]. This study reported the presence of isoform 2 of beta-
tropomyosin in the cancerous tissues of  26.7%  from the study population and it was 
undetectable in all the normal tissues of the patients. The detected beta-tropomyosin is 
either a new isoform or a truncated form because it contain 257 amino acids while the 
other forms contain 284, 284 and 248 amino acids. The probability that this protein is a 
new isoform rather than a truncated form was shown by Ben Yousef and Francomano 
when they sequenced the gene of human beta-tropomyosin and found that it is composed 
of 257 nucleotides [87].   
Monoclonal antibody production: 
          Monoclonal antibodies have been produced with low concentration 0.35mg/ml 
compared to ideal situation 1-5mg/ml [56].The low productivity may be due to that 
growth factors and feeder cells were not used due to financial and political issues. Two 
tests were done in order to determine specificity of the produced monoclonal antibody. 
The monoclonal antibody has shown some specificity since they did not bind the casein 
and the BSA. The number of peptides and the molecular weight of the monoclonal 
antibody has been determined. However the full determination of the specificity requires 
western blot analysis and immunohistochemistry tests [88]. The western blot analysis was 
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not done due to that the amount of the  beta-tropomyosin of the 2D PAGE gels were not 
enough for the immunization, ELISA  and the specificity determination tests. Regarding 
the immunohistochemistry tests, the tissues were not enough because the 2D PAGE 
analysis was done 2-4 times for the positive tissues so as to obtain enough antigen 
concentration for immunization and ELISA tests.  
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CHAPTER FOUR 
 Conclusions 
 
1- Breast cancer tissues are characterized by abnormal proteins with the presence in 
one third of the study population. 
2- The abnormal proteins were Thioredoxin (D60n mutant) , X-ray crystal structure 
of human galectin-1, rcTPM3 and beta- tropomyosin (isoform 2).  
3- The presence of the abnormal proteins in one third of the study population  
strongly directs towards individualization of diagnosis and treatment of breast 
cancer patients. 
4- Monoclonal antibodies against beta-tropomyosin has been produced. The 
specificity tests have shown that it does not react non specifically, but the western 
blot and immunohistochemistry tests were not done. 
5- The number of bands and the molecular weight of the monoclonal antibody were 
determined.  
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CHAPTER FOUR 
Recommendations 
Further studies in multi centers are needed with: 
1- Large number of patients to verify the presence of the abnormal antigens in the 
studied population.  
2- Involvement of different stages and grades of breast cancer. 
3- Adequate  amount of the tissue (10 grams at least). 
4- Full antibody characterization should be done. 
5- Clinical research to find the association of presence of the abnormal antigens and the 
aggressiveness of the tumour, response to therapy or prognosis.  
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CHAPTER FOUR 
Annexes 
Annex 1 ProteoPrep® sample extraction kit protocol. 
1- Suspend 3 grams of sample in 2ml of reagent 1, 2, 3 or 4 and sonicate on ice 
            ( 4 ×15 seconds ) using ultra sonic probe. 
2- centrifuge the suspension at 15000 × g for 30 minutes at 15˚C. 
3- Decant the supernatant into a clean tube and discard the insoluble pellet. 
4- Reduce the supernatant by adding 50 µl of TBP ( Tributylphosphine ). 
5- Alkylate the solution by adding 60 µl  of iodoacetamide. 
6- Centrifuge at 20000 × g for five minutes at room temperature. 
7- Determine the concentration of the protein and Load on Iso Electric focusing gels.  
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Annex 2 Protein A antibody purification kit protocol (SIGMA PURE1A). 
1- To each 10 ml of culture supernatant, add one ml of binding buffer and mix well. 
2- Fill a 10 ml syringe with 10 ml HEPES buffer and connect it to the top of the 
desalting cartridge. Regenerate the cartridge by passing the buffer through the 
cartridge at an approximate flow rate 1 ml/min. 
3- Fill a 5 ml syringe with five ml of regeneration buffer and connect it to the top of 
the of the protein A cartridge. Regenerate the cartridge by passing the buffer 
through the cartridge at an approximate flow rate of 1 ml/min. 
4- Fill a 10 ml syringe with 4 ml of binding buffer . Equilibrate the protein A 
cartridge by passing the buffer through the cartridge at an approximate flow rate 
of 1 ml/min.  
5- Fill a 10 ml syringe with the sample-binding buffer mixture. Load the protein A 
cartridge by passing the sample – binding buffer mixture through the cartridge at 
an approximate flow rate of 0.5 ml/min.  
6- After the sample is loaded on the protein A cartridge, rinse the 10 ml syrine with 
water , refill it with 6 ml of binding buffer and wash the protein A cartridge by 
passing the buffer through the cartridge at an approximate flow rate of 1 ml/min.  
7- Attach the female end of the protein A cartridge to the male Leur lock fitting of 
desalting cartridge. 
8- Fill the 5 ml syringe with 5 ml of elution buffer. Attach the syringe to the protein 
A cartridge. Elute the cartridges by passing the elution buffer through the 
cartridges at approximate flow rate of 0.5 ml/min. The elute contains the purified 
immunoglobulin at a physiological pH.  
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9- Detach the two cartridges. A- Regenerate the protein A cartridge by passing 5 ml 
of regeneration buffer through the cartridge. B- Regenerate the desalting cartridge 
by passing 10 ml of HEPES buffer through the cartridge. The cartridges are now 
ready for another affinity chromatographic purification. 
10- For the long term storage of the cartridges, wash the cartridges with 10 ml 
phosphate buffered saline containing 0.02% sodium azide. Cap the cartridges with 
the end closures provided and store at 2-8˚C.  
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Annex.3 Immunized mouse (red color label marked) 
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Annex.4 Immunized mouse ( Green color label marked ). 
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Annex.5 Control mouse ( white color label marked ). 
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Annex.6 The spleen of the sacrificed mouse. 
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Annex.7 Published papers   
1- Ahamed M.E, Mohamed A O, Ahmed M E, Sirinuch B, Surasak J. Protein content     
     study revealed revealed presence of isoform 2 of beta-tropomyosin in primary breast  
     cancer tissues from Sudanese patients .Sudan J. Med. Sci 2007; 2:183-187. 
 
2- Ahamed M E, Ahmed M E, Eltoum A M, Eltahir G O, Ahmed K M, Harbi S O,  
     Johnson S, Mohamed A O. Abnormal proteins in primary breast cancer tissues from      
     25 Sudanese patients. European Journal of Inflammation 2008; 6(3): 115- 121. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
91 
 
Annex.8 Information Entry in SWISSPROT database 
4 results for author:"Ahamed M.E."  in UniProtKB 
Page 1 of 1 
All Accession  Entry name  Protein names  Gene names  Length 
 P09382 LEG1_HUMAN Galectin-1  LGALS1 135 
 P10599 THIO_HUMAN Thioredoxin  TXN (TRDX) (TRX) (TRX1) 
105 
 P07951 TPM2_HUMAN Tropomyosin beta chain
TPM2 (TMSB) 284 
 P06753 TPM3_HUMAN Tropomyosin alpha-3 chain
TPM3 284 
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